STUDY ON THE THERAPEUTIC EFFECT OFPANIPENEM/BETAMIPRON ON PERINATAL INFECTION IN PREGNANT WOMEN

DOI PubMed 8 References
  • MIKAMO HIROSHIGE
    Department of Obstetrics and Gynecology, School of Medicine, Gifu University
  • KAWAZOE KYOKO
    Department of Obstetrics and Gynecology, School of Medicine, Gifu University
  • SATO YASUMASA
    Department of Obstetrics and Gynecology, School of Medicine, Gifu University
  • HAYASAKI YOH
    Department of Obstetrics and Gynecology, School of Medicine, Gifu University
  • TAMAYA TERUHIKO
    Department of Obstetrics and Gynecology, School of Medicine, Gifu University
  • IZUMI KOJI
    Department of Obstetrics and Gynecology, Ibi General Hospital
  • ITO KUNIHIKO
    Department of Obstetrics and Gynecology, Gifu Municipal Hospital
  • YAMADA YOSHITAKA
    Department of Obstetrics and Gynecology, Gifu Prefectural Gifu Hospital

Bibliographic Information

Other Title
  • 周産期におけるカルバペネム系抗菌薬パニペネム・ベタミプロンの治療効果

Search this article

Abstract

An investigation was carried out to determine the therapeutic effect of panipenem/betamipron (PAPM/BP), ainjectable carbapenem antimicrobial agent, on infections in pregnant women during perinatal period. Of the 41patients enrolled in the study, 34 were subjected to the analysis, with 1 exemption because of protocol violations (regimen), 3 because of uncertain evidence symptoms of infection, and 3 because of failure to undergo laboratorytests. PAPM/BP was administered by intravenous drip infusion at doses of 0.5g twice or three times a day dailyfor periods of 3 to 14 days. The efficacy rate according to the evaluation of the Drug Efficacy Evaluation Committeeand the attending physicians was 79.4% (27/34), with 49 of the 61 clinical isolates (80.3%) being eradicated.Safety was evaluated as “safe” in 39 of the 41 assessable patients (94.1%). Mild headache and nausea wereexperienced by 1 patient (2.4%) as adverse drug reactions, but the symptoms disappeared after the completion oftreatment. Slight elevations of GOT, GPT and LDH in laboratory tests were observed in 1 patient (2.4%), but these values returned to normal after the completion of treatment. These results suggested that PAPM/BP may bea useful drug in the treatment of bacterial infections during the perinatal period. To firmly establish its safety, however, further clinical and pharmacokinetic studies are needed in larger populations.

Journal

References(8)*help

See more

Details 詳細情報について

Report a problem

Back to top